Data presented herein not only provide novel mechanistic insights into the roles of IL-33 and ILC2s in promoting metabolic homeostasis, but they also raise the potential beneficial therapeutic use of type 2-inducing RNases in the treatment and management of obesity and obesity-related metabolic disorders. Here, IL33 is linked to Other metabolic disease.